Topics

Arecor Signs A New Formulation Evaluation Agreement With An Existing Partner, A Major Global Pharmaceutical Company

03:08 EDT 9 Jul 2019 | OBN

Arecor Limited (“Arecor” or “the Company”), the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, today announces that it has signed a further collaboration with a major global pharmaceutical company.

Original Article: Arecor Signs A New Formulation Evaluation Agreement With An Existing Partner, A Major Global Pharmaceutical Company

NEXT ARTICLE

More From BioPortfolio on "Arecor Signs A New Formulation Evaluation Agreement With An Existing Partner, A Major Global Pharmaceutical Company"

Quick Search

Relevant Topic

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...